Larimar Therapeutics Evaluates Nomlabofusp in Pediatric Friedreich's Ataxia Trial
Larimar Therapeutics is conducting a clinical trial to assess the safety and tolerability of nomlabofusp in adolescents and children with Friedreich's ataxia.
Company
Pharmaceutical intelligence for Larimar Therapeutics with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.